RecruitingAtopic Dermatitis
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
You may qualify if…
- ✓ 1. Male or female subjects between 18 and 75 years of age.
- ✓ 2. Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 1 year
- ✓ 3. Documented recent history of inadequate response to TCS or TCI, or for whom topical treatments are otherwise medically inadvisable.
- ✓ 4. Subjects must meet the following criteria for disease activity:
- ✓ Eczema Area and Severity Index (EASI) score ≥ 16 ;
- ✓ (Body Surface Area )BSA affected by AD ≥ 10% ;
- ✓ (validated Investigator's Global Assessment-AD)vIGA-AD score ≥3 ;
- ✓ Baseline weekly average of daily Worst Pruritus NRS ≥ 4.
You may not qualify if…
- ✕ 1. Lack of response or inadequate response to prior treatment with any JAK inhibitor for AD.
- ✕ 2. Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions.
- ✕ 3. Pregnant or breastfeeding females.
- ✕ 4. History of any clinically major diseases, with the exception of atopic dermatitis.
- ✕ 5. Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive ICP-332 or participate in this study.
Source: ClinicalTrials.gov · NCT06775860 · last updated 2025-09-08